3 stories mentioning BBOTUpdated 31d ago
Every FINWIRES story that references BBOT, newest first.
BridgeBio Oncology Therapeutics, Inc. (BBOT) has an average rating of buy and mean price target of $25.30, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
BridgeBio Oncology Therapeutics (BBOT) has an average rating of buy and mean price target of $25.11, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
BridgeBio Oncology Therapeutics (BBOT) said Wednesday its chief scientific officer Pedro Beltran has been appointed as chief executive officer of the company.Idan Elmelech has also been appointed as chief operating officer, and Neil Kumar its executive chairman, BridgeBio said.Elmelech previously served as senior vice president of strategy & business development, and Kumar played an integral role in the founding of BBOT as part of BridgeBio Pharma, the firm said.Beltran succeeds Eli Wallace, who will transition into the a senior adviser role, the company said.Price: $8.89, Change: $-0.57, Percent Change: -6.03%
